Xiangxue Pharmaceutical - Asset Resilience Ratio

Latest as of March 2024: 0.05%

Xiangxue Pharmaceutical (300147) has an Asset Resilience Ratio of 0.05% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥4.00 Million

≈ $585.33K USD Cash + Short-term Investments

Total Assets

CN¥8.24 Billion

≈ $1.21 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2010–2024)

This chart shows how Xiangxue Pharmaceutical's Asset Resilience Ratio has changed over time. Check 300147 strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Xiangxue Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Xiangxue Pharmaceutical (300147) market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥4.00 Million	0.05%
Total Liquid Assets	CN¥4.00 Million	0.05%

Asset Resilience Insights

Limited Liquidity: Xiangxue Pharmaceutical maintains only 0.05% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Xiangxue Pharmaceutical Industry Peers by Asset Resilience Ratio

Compare Xiangxue Pharmaceutical's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Sk Biopharmaceuticals Co Ltd KO:326030	Biotechnology	0.14%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
Hangzhou Biotest Biotech Co Ltd SHG:688767	Biotechnology	0.56%
Theravance Biopharma Inc F:0TB	Biotechnology	37.29%

Annual Asset Resilience Ratio for Xiangxue Pharmaceutical (2010–2024)

The table below shows the annual Asset Resilience Ratio data for Xiangxue Pharmaceutical.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	0.17%	CN¥13.00 Million ≈ $1.90 Million	CN¥7.50 Billion ≈ $1.10 Billion	+0.67pp
2023-12-31	-0.49%	CN¥-40.87 Million ≈ $-5.98 Million	CN¥8.28 Billion ≈ $1.21 Billion	-0.49pp
2022-12-31	0.00%	CN¥125.98K ≈ $18.43K	CN¥9.35 Billion ≈ $1.37 Billion	-0.58pp
2021-12-31	0.58%	CN¥65.63 Million ≈ $9.60 Million	CN¥11.38 Billion ≈ $1.67 Billion	+0.38pp
2020-12-31	0.20%	CN¥19.34 Million ≈ $2.83 Million	CN¥9.78 Billion ≈ $1.43 Billion	-0.14pp
2019-12-31	0.34%	CN¥28.54 Million ≈ $4.18 Million	CN¥8.46 Billion ≈ $1.24 Billion	+0.07pp
2018-12-31	0.27%	CN¥23.34 Million ≈ $3.41 Million	CN¥8.63 Billion ≈ $1.26 Billion	+0.44pp
2017-12-31	-0.17%	CN¥-16.17 Million ≈ $-2.37 Million	CN¥9.44 Billion ≈ $1.38 Billion	-0.50pp
2016-12-31	0.33%	CN¥26.36 Million ≈ $3.86 Million	CN¥7.99 Billion ≈ $1.17 Billion	-0.13pp
2015-12-31	0.46%	CN¥21.27 Million ≈ $3.11 Million	CN¥4.65 Billion ≈ $680.73 Million	+0.64pp
2014-12-31	-0.18%	CN¥-6.46 Million ≈ $-944.87K	CN¥3.59 Billion ≈ $525.08 Million	-0.19pp
2010-12-31	0.01%	CN¥203.67K ≈ $29.80K	CN¥1.85 Billion ≈ $270.22 Million	--

pp = percentage points

About Xiangxue Pharmaceutical

SHE:300147 China Biotechnology

Market Cap

$658.01 Million

CN¥4.50 Billion CNY

Market Cap Rank

#10790 Global

#2917 in China

Share Price

CN¥6.80

Change (1 day)

+0.74%

52-Week Range

CN¥6.26 - CN¥11.74

All Time High

CN¥25.81